CBIO
Crescent Biopharma
CBIO
CBIO
55 hedge funds and large institutions have $61.9M invested in Crescent Biopharma in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 19 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.02% less ownership
Funds ownership: 0.58% → 0.55% (-0.02%)
68% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 19
Holders
55
Holding in Top 10
–
Calls
$247K
Puts
$120K
Top Buyers
| 1 | +$235K | |
| 2 | +$123K | |
| 3 | +$94.2K | |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$52.2K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$44.4K |
Top Sellers
| 1 | -$717K | |
| 2 | -$438K | |
| 3 | -$315K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$255K |
| 5 |
Two Sigma Advisers
New York
|
-$250K |